Close Menu

translational genomics

The companies aim to develop technologies for interpreting cancer genome data, with a focus on linking genetic profiles with treatment responses.

In a survey conducted by an association working group, 40 percent of respondents said they are already offering TMB, with most others planning to do the same within the year.

Microsoft is applying its Project Hanover AI to Jackson Laboratory's Clinical Knowledgebase to help tumor boards find appropriate therapies based on tumor mutations.

With a $3.7 million NIH grant, database developers hope to garner FDA recognition, develop a new user interface, and further integrate its use in cancer care.

The data add to growing evidence supporting the use of HER2 therapy across solid tumors, though researchers find a difficult path to a tissue-agnostic approval.

Tumor genomes from almost 2,400 patients with metastatic cancer revealed a range of somatic alterations, providing a foundation for clinical sequencing efforts.

The early-stage genomics-based trials suggest tumor sequence can be informative for late-stage cancers, as an ESMO group seeks clinically meaningful translation.

Since 2016, the VHA has routinely profiled molecular features in advanced cancers from vets in its care, even in rural locales, though challenges remain.

In response to CMS reopening its national coverage determination to address its germline testing policy, stakeholders point out areas of concern and confusion.